Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Reinisch

Showing results (281-290 of 352) with videos related to

Pageof 36
Sort By:
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 studySilvio Danese, Jean-Frederic Colombel, Milan Lukas, et al.
Gastroenterology|July 15, 2009
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximabWilliam J Sandborn, Paul Rutgeerts, Brian G Feagan, et al.
Gut|October 21, 2020
Effect of IBD medications on COVID-19 outcomes: results from an international registryRyan C Ungaro, Erica J Brenner, Richard B Gearry, et al.
Therapeutic Advances in Gastroenterology|October 13, 2025
Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysisMarc Ferrante, Laurent Peyrin-Biroulet, Perttu Arkkila, et al.
Journal of Crohn'S & Colitis|December 22, 2010
IBD patients need in health quality of care ECCO consensusMargarita Elkjaer, Gabrielle Moser, Walter Reinisch, et al.
Gastroenterology|March 7, 2016
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic ResectionMiguel Regueiro, Brian G Feagan, Bin Zou, et al.
Inflammatory Bowel Diseases|August 24, 2021
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II StudyGeert R D'Haens, Walter Reinisch, Scott D Lee, et al.
Frontiers in Medicine|February 27, 2023
The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccinationSelma Tobudic, Elisabeth Simader, Thomas Deimel, et al.
Journal of Crohn'S & Colitis|September 27, 2021
Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger PatientsAmanda Ricciuto, Christopher A Lamb, Eric I Benchimol, et al.
Journal of Crohn'S & Colitis|February 18, 2021
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT IIWalter Reinisch, William J Sandborn, Silvio Danese, et al.
Pageof 36

Showing results (281-290 of 352) with videos related to

Sort By:
Pageof 36
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 studySilvio Danese, Jean-Frederic Colombel, Milan Lukas, et al.
Gastroenterology|July 15, 2009
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximabWilliam J Sandborn, Paul Rutgeerts, Brian G Feagan, et al.
Gut|October 21, 2020
Effect of IBD medications on COVID-19 outcomes: results from an international registryRyan C Ungaro, Erica J Brenner, Richard B Gearry, et al.
Therapeutic Advances in Gastroenterology|October 13, 2025
Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysisMarc Ferrante, Laurent Peyrin-Biroulet, Perttu Arkkila, et al.
Journal of Crohn'S & Colitis|December 22, 2010
IBD patients need in health quality of care ECCO consensusMargarita Elkjaer, Gabrielle Moser, Walter Reinisch, et al.
Gastroenterology|March 7, 2016
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic ResectionMiguel Regueiro, Brian G Feagan, Bin Zou, et al.
Inflammatory Bowel Diseases|August 24, 2021
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II StudyGeert R D'Haens, Walter Reinisch, Scott D Lee, et al.
Frontiers in Medicine|February 27, 2023
The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccinationSelma Tobudic, Elisabeth Simader, Thomas Deimel, et al.
Journal of Crohn'S & Colitis|September 27, 2021
Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger PatientsAmanda Ricciuto, Christopher A Lamb, Eric I Benchimol, et al.
Journal of Crohn'S & Colitis|February 18, 2021
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT IIWalter Reinisch, William J Sandborn, Silvio Danese, et al.
Pageof 36